Accuray Incorporated (ARAY) CFO Sells $13,936.05 in Stock

Accuray Incorporated (NASDAQ:ARAY) CFO Kevin Waters sold 2,997 shares of the firm’s stock in a transaction dated Tuesday, April 3rd. The stock was sold at an average price of $4.65, for a total value of $13,936.05. Following the completion of the sale, the chief financial officer now directly owns 328,260 shares in the company, valued at $1,526,409. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Accuray stock opened at $4.85 on Friday. The stock has a market capitalization of $400.88, a PE ratio of -13.47 and a beta of 1.73. The company has a current ratio of 1.54, a quick ratio of 0.99 and a debt-to-equity ratio of 2.66. Accuray Incorporated has a 12 month low of $3.60 and a 12 month high of $6.15.

How to Become a New Pot Stock Millionaire

Accuray (NASDAQ:ARAY) last released its quarterly earnings data on Tuesday, January 23rd. The medical equipment provider reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.05. The company had revenue of $100.33 million for the quarter, compared to the consensus estimate of $90.31 million. Accuray had a negative return on equity of 44.66% and a negative net margin of 6.09%. The company’s quarterly revenue was up 14.7% compared to the same quarter last year. During the same period last year, the business posted ($0.11) EPS. equities analysts forecast that Accuray Incorporated will post -0.19 earnings per share for the current fiscal year.

ARAY has been the topic of a number of research analyst reports. BidaskClub lowered Accuray from a “buy” rating to a “hold” rating in a research note on Tuesday, December 12th. JPMorgan Chase lowered Accuray from a “neutral” rating to an “underweight” rating and set a $6.00 price target on the stock. in a research note on Wednesday, December 13th. Royal Bank of Canada set a $6.00 price target on Accuray and gave the stock a “hold” rating in a research note on Wednesday, January 24th. Finally, Zacks Investment Research raised Accuray from a “sell” rating to a “buy” rating and set a $6.50 price target on the stock in a research note on Friday, January 26th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $7.21.

Several institutional investors have recently added to or reduced their stakes in ARAY. Teacher Retirement System of Texas purchased a new position in shares of Accuray in the 4th quarter worth about $128,000. MetLife Investment Advisors LLC purchased a new position in shares of Accuray in the 4th quarter worth about $160,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Accuray in the 3rd quarter worth about $191,000. Wells Fargo & Company MN raised its holdings in shares of Accuray by 52.5% in the 3rd quarter. Wells Fargo & Company MN now owns 94,664 shares of the medical equipment provider’s stock worth $379,000 after purchasing an additional 32,605 shares during the period. Finally, Centiva Capital LP purchased a new position in shares of Accuray in the 4th quarter worth about $458,000. Institutional investors own 82.00% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first published by Ticker Report and is owned by of Ticker Report. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.tickerreport.com/banking-finance/3335307/accuray-incorporated-aray-cfo-sells-13936-05-in-stock.html.

Accuray Company Profile

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.

Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Pabyosi Coin  Trading 10% Higher  This Week
Pabyosi Coin Trading 10% Higher This Week
Bolenum 24 Hour Volume Hits $177.00
Bolenum 24 Hour Volume Hits $177.00
Polaris Industries  Given Consensus Recommendation of “Hold” by Brokerages
Polaris Industries Given Consensus Recommendation of “Hold” by Brokerages
Viper Energy Partners  Given Consensus Recommendation of “Buy” by Brokerages
Viper Energy Partners Given Consensus Recommendation of “Buy” by Brokerages
Deckers Outdoor Co.  Expected to Announce Quarterly Sales of $377.25 Million
Deckers Outdoor Co. Expected to Announce Quarterly Sales of $377.25 Million
TimkenSteel  Expected to Announce Quarterly Sales of $372.53 Million
TimkenSteel Expected to Announce Quarterly Sales of $372.53 Million


© 2006-2018 Ticker Report. Google+.